NCT05536973: Safety and Efficacy of ADVM-022 in Treatment-Experienced Patients With Neovascular Age-related Macular Degeneration [LUNA]
- State
- Under way
- Phase
- Phase 2
- People
- 69 taking part
- Started
- 23 Aug 2022
- Primary completion
- 26 Aug 2024
- Arms
- Dose 1, Dose 2
- Results
- None posted
- 23 Aug 2022: Trial started
- 13 Sep 2022: Trial registered